Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

9.4K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.4K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

5.3K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.3K
Tumor Progression02:07

Tumor Progression

7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Ultrasound priming gated by solid tumor hallmarks to guide CAR-T therapy.

Science advances·2026
Same author

Application of Label-Free Detection Using Tapered Optical Fiber System for Head and Neck Cancer and Infectious Biomolecules.

Head & neck·2026
Same author

ETS1 Orchestrates a Hybrid EMT Program Driving Metastasis and Immune Evasion.

Cancer research·2026
Same author

Tissue regenerative medicine: Clinical advances, challenges, and opportunities.

APL bioengineering·2025
Same author

A high-power spatial, single-cell view of pericytes in esophageal cancer metastasis.

Nature genetics·2025
Same author

Genomic and Single-Cell Analyses Characterize Patient-Derived Tumor Organoids to Enable Personalized Therapy for Head and Neck Squamous Cell Carcinoma.

Cancer research·2025

相关实验视频

Updated: Jan 15, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.8K

精确表观遗传重编程:CoREST抑制使STK11突变瘤对免疫检查点阻塞疗法的敏感.

De-Chen Lin1, Keyue Shen2

  • 1Center for Craniofacial Molecular Biology, Herman Ostrow School of Dentistry, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.

Cancer research
|October 15, 2025
PubMed
概括

在STK11 (也称为LKB1) 中的功能丧失突变导致非小细胞肺癌对免疫治疗的耐药性. 用TNG260准CoREST复合体恢复了免疫敏感性,并提高了抗PD-1疗法的疗效.

更多相关视频

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.5K
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

2.5K

相关实验视频

Last Updated: Jan 15, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.8K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.5K
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

2.5K

科学领域:

  • 在瘤学瘤学.
  • 免疫学 免疫学 免疫学
  • 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.

背景情况:

  • 在STK11 (也称为LKB1) 中的功能丧失突变标志着一种抗免疫检查点阻塞的非小细胞肺癌亚型.
  • 在STK11突变瘤中,免疫逃避与表观遗传失调有关.
  • 损伤的T细胞透和抑制的抗原呈现有助于治疗耐药性.

研究的目的:

  • 识别和药理上针对STK11突变非小细胞肺癌的脆弱性,以恢复免疫敏感性.
  • 在临床前模型和早期临床试验中评估新型CoREST复合抑制剂TNG260的疗效.

主要方法:

  • 通过基因素脱乙酶1识别CoREST复合体,作为治疗点.
  • 开发和测试TNG260,一种选择性小分子CoREST抑制剂.
  • 在STK11缺乏非小细胞肺癌模型的临床前研究和早期临床试验数据的分析 (NCT05887492).

主要成果:

  • 在STK11缺陷模型中,TNG260重新编程瘤表观基因组,提高免疫基因的调节.
  • 在临床前研究中,TNG260与抗PD-1疗法协同作用,导致持续的瘤回归.
  • 早期临床数据显示,在接受TNG260和pembrolizumab治疗的患者中,基因组乙化和CD8+T细胞透率增加.

结论:

  • 在STK11突变非小细胞肺癌中,CoREST复合体是一种可用药物的脆弱性.
  • 对CoREST的药理抑制可以恢复免疫敏感性并提高免疫治疗的疗效.
  • 需要进一步研究耐久性,瘤类型特异性和生物标志物策略.